MU crossed $1,000 this week, recovered 9% on the week to $1,020, and then gave back 6% on Tuesday — all while the clock ticks toward June 24 earnings and options traders build their most defensive posture in months.
The options signal is the sharpest thing in this week's data. The put/call ratio has climbed to 1.33, running above its 20-day average of 1.26 and within touching distance of the 52-week high of 1.37. The z-score, at 1.16, isn't extreme on its own — but the direction matters: the PCR has drifted steadily higher since mid-May, when it was printing around 1.15. That's a slow, deliberate accumulation of downside protection, not a panic hedge. With earnings seven days out and the stock up 41% in a month, traders are not taking the rally for granted.
The lending market tells a completely different story — there is no short-side pressure here. Borrow availability is effectively unlimited, with over a billion shares available in the lending pool. Short interest holds at 3.3% of the free float, a level that has barely moved in a month despite the stock nearly doubling off its lows. Cost to borrow has doubled from its mid-May floor to 0.42%, but that still qualifies as low in absolute terms. The ORTEX short score sits at 31, well into the low-conviction-shorts territory. This is not a setup where bears are loading up aggressively — the caution is in options, not in the borrow market.
The analyst wave has continued to roll in, and the numbers have now grown to the point of genuine drama. Deutsche Bank raised its target to $1,500 on Tuesday. TD Cowen lifted to $1,500 earlier in the week, up from $660. RBC went to $1,200 from $525. The consensus mean now prints at $888, still well below where the stock trades — a gap that reflects how far the stock has run ahead of the Street's ability to reprice. Goldman remains the outlier: a $900 target with a Neutral rating, now 12% below the current price. Every other firm on the recent list sits Overweight or Outperform. The bull case rests on HBM leadership and AI-driven data centre demand; the bear case points to cyclicality and the risk that DRAM pricing rolls over in the next downturn. EPS momentum scores are exceptional — 92nd percentile over 30 days, 97th over 90 days — but the 12-month forward EPS growth estimate has turned negative, which is the quiet contradiction underneath the bullish consensus.
CEO Sanjay Mehrotra sold roughly $10 million worth of stock on May 29 across multiple tranches, all priced between $948 and $974. The trades carry a low significance score and look like scheduled disposals rather than a directional call — but the timing, with the stock now trading 5% above those sale prices, is worth noting. On the institutional side, BlackRock added 2.4 million shares through May 31, reinforcing its position as the largest holder at 9.1% of shares outstanding. JP Morgan Asset Management added nearly a million shares through June 1. The passive and semi-passive money continues to accumulate.
The last earnings print, in March, produced a 3.8% drop on the day and a 17% decline over the following five sessions — a pattern that is now directly relevant. The stock enters June 24 up 41% in a month and sitting above most analyst price targets. What to watch is not whether MU can report a strong number — the Street already assumes it will — but whether guidance on HBM pricing and DRAM margins justifies a stock that has moved well ahead of even the most recently refreshed consensus.
See the live data behind this article on ORTEX.
Open MU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
